Country: Írland
Tungumál: enska
Heimild: HPRA (Health Products Regulatory Authority)
PSEUDOEPHEDRINE HYDROCHLORIDE
Cupal Limited
PSEUDOEPHEDRINE HYDROCHLORIDE
30 MG/5ml
Oral Solution
Product not subject to medical prescription
Withdrawn
2010-04-28
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Meltus Decongestant 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pseudoephedrine hydrochloride 30 mg/5ml. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Oral Liquid 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS As a nasal decongestant. For the short term symptomatic relief of conditions such as the common cold and influenza, allergic and vasomotor rhinitis (relief of such symptoms as blocked sinuses, stuffed up noses). 4.2 POSOLOGY AND METHOD OF ADMINSTRATION Route of administration: oral To be taken three times a day Adults and children over 12 years: two 5ml spoonfuls. Children 6-12 years: one 5ml spoonful. Children 2-5 years: one 2.5ml spoonful. Under 2 years: not recommended. 4.3 CONTRAINDICATIONS Contraindicated in patients who have previously shown intolerance to pseudoephedrine. It is contraindicated in persons under treatment with MAOIs, and within 2 weeks of cessation of treatment. It is also contraindicated in patients with severe hypertension or severe coronary artery disease. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Although pseudoephedrine has virtually no pressor effects in patients with normal blood pressure, Meltus Decongestant should be used with caution in patients taking antihypertensive agents, tricyclic anti-depressants, or other sympathomimetic agents such as decongestants, appetite suppressants and amphetamine like psycho-stimulants. The effects of a single dose on the blood pressure of these patients should be observed before recommending repeated or unsupervised treatment. As with other sympathomimetic agents, caution should be exercised in patients with uncontrolled diabetes, hyperthyroidism, elevated intraocular pressure and prostatic enlargement. IRISH MEDICINES BOARD __________________________ Lestu allt skjalið